Core Insights - Evofem Biosciences, Inc. has successfully concluded its "Say Vagina" campaign, which aimed to normalize clinical anatomical language and combat censorship in medical terminology, resulting in significant engagement and awareness [1][3][9] - The campaign led to a 130% increase in traffic to PHEXXI.com, making PHEXXI the most followed contraceptive brand on social media among healthcare providers [1][9] - Evofem plans to maintain the momentum from the campaign by launching SayVaginaStore.com, with proceeds from merchandise sales going to sexual and reproductive health charities [3] Company Overview - Evofem is focused on commercializing innovative products to address unmet needs in women's sexual and reproductive health, generating revenue from two FDA-approved products: PHEXXI and SOLOSEC [4][6] - PHEXXI is the first and only hormone-free, on-demand prescription contraceptive vaginal gel, while SOLOSEC is an FDA-approved oral antibiotic for treating bacterial vaginosis and trichomoniasis [5][6] Campaign Impact - The "Say Vagina" campaign generated over 2.5 million views across social media platforms and significantly increased engagement with patients, providers, and educators [9] - CEO Saundra Pelletier emphasized the campaign's role in transforming shame into empowerment and fostering open dialogue about women's health [3] Future Plans - Evofem is preparing for a Special Meeting of Stockholders on September 26, 2025, to discuss a merger with Aditxt, Inc., which will result in Evofem becoming a wholly owned subsidiary of Aditxt [8][10][14]

Core Viewpoint - Evofem Biosciences reported a 16% increase in net sales for Q2 2025 compared to the same quarter last year, driven by the addition of SOLOSEC and a price increase for PHEXXI, while also improving its loss from operations [2][3][4]. Financial Performance - Net sales for Q2 2025 were $4.8 million, up from $4.2 million in Q2 2024 [3][6]. - Total operating expenses increased to $6.1 million in Q2 2025 from $5.5 million in the prior year [3][7]. - Loss from operations improved to $1.3 million in Q2 2025, compared to $1.4 million in Q2 2024 [4][6]. - Net loss attributable to common stockholders was $1.8 million in Q2 2025, a decline from a net income of $1.3 million in Q2 2024, resulting in a net loss of $(0.02) per share [4][18]. Liquidity and Capital Raising - Evofem raised $2.4 million in net proceeds from the sale of senior subordinated notes and warrants to Aditxt, Inc. in April and June 2025 [5][8]. - As of June 30, 2025, the company had cash and cash equivalents of $0.7 million [8]. Strategic Developments - Evofem is advancing plans for a Special Meeting of Stockholders to approve the A&R Merger Agreement with Aditxt, which will make Evofem a wholly-owned subsidiary of Aditxt [5][11]. - The company is working on reducing manufacturing costs by approximately 50% for PHEXXI and SOLOSEC to enhance profitability and market entry [6]. Market Initiatives - PHEXXI gained significant attention through a viral TikTok campaign, achieving over 7 million views and 24,000+ comments [6]. - Evofem declared August as "Say Vagina Month" to promote awareness and engagement around vaginal health, resulting in a 250% increase in unique visits to Phexxi.com during the campaign's first week [6]. Product Approvals and Trials - PHEXXI has been submitted for marketing approval in the UAE, with SOLOSEC expected to follow in Q3 2025 [6][10]. - Patient recruitment is ongoing for a Phase 4 clinical trial evaluating SOLOSEC's effectiveness compared to metronidazole for treating Trichomonas vaginalis [6].

As filed with the Securities and Exchange Commission on August 10, 2023 Registration Statement No. 333-273185 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT No. 2 To FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 EVOFEM BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 20-8527075 (I.R.S. Employer Iden ...